We are strengthening our foundation of care, advocacy, and education efforts by finding the best treatment and prevention options to allow our patients to live their healthiest lives.

Our Work

Whitman-Walker’s research studies include clinical trials to test promising, not-yet approved medications, as well as long-term cohort studies that improve treatment for our patients. Our commitment to community has helped us expand our work to include studies focused on transgender and youth patients.
In January 2020, we rolled out a study of a preventive HIV vaccine as part of the only ongoing Phase 3 HIV vaccine trial in the United States.
We currently have more than 2,500 participants in 40+ active studies.
We participate in $2 million of clinical trials annually.

Our Impact

Whitman-Walker has been conducting clinical research studies and pharmaceutical trials since the advent of HIV medication in 1987. Our participation in these studies have impacted thousands of lives with HIV and Hep C treatment regimens, as well as methods of prevention, to keep our communities and the nation protected from contracting HIV.
Since the founding of our research program, we’ve:

Studied nearly every HIV and Hepatitis C medication on the market

Helped develop new treatments for Hepatitis B and C

Demonstrated the feasibility of transferring PrEP from research to clinical practice

Became the first federally qualified health center (FQHC) to be selected as a clinical research site as part of the NIH federally funded AIDS Clinical Trial Group (ACTG) grant

Published research on transgender people to elevate the health care needs of this significantly underserved population

Partnered with community health centers and providers across the country to grow and share knowledge of caring for the diverse populations we serve